Ab­b­Vie seeks Resta­sis fol­low-up with small op­tion fee for Aldeyra’s eye drops, de­spite a po­ten­tial 'im­mi­nen­t' CRL

As Ab­b­Vie’s sales of its dry eye dis­ease drug Resta­sis con­tin­ue to slide fol­low­ing the first gener­ic ap­proval in Feb­ru­ary 2022, the Big Phar­ma is now mak­ing a small bet to po­ten­tial­ly re­gain pos­ture in the space, which Bausch + Lomb is eat­ing in­to with its re­cent pur­chase of No­var­tis’ Xi­idra.

Ab­b­Vie is pay­ing Aldeyra Ther­a­peu­tics $1 mil­lion in ex­change for the op­tion for the co-ex­clu­sive li­cense to de­vel­op, man­u­fac­ture and mar­ket the biotech’s eye drops, known as re­prox­alap, in the US. The Chica­go-area phar­ma gi­ant could al­so nab the ex­clu­sive li­cense out­side the coun­try.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER